PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
Marketing Manager, Antigenics
The animation provided such a clear explanation of our technology and was extremely well received. Representatives of several exhibiting companies expressed their interest in contacting you for their own projects!